학술논문
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy
Document Type
Article
Author
Source
In Molecular Therapy - Nucleic Acids 8 March 2022 27:1179-1190
Subject
Language
ISSN
2162-2531